Director/PDMR Shareholding

RNS Number : 5307K

Feedback PLC

22 December 2022

 

Feedback plc

Director Dealings  

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the frontline clinical technology company, announces the following Directors' dealings:

Rory Shaw, Non Executive Chairman, has subscribed for 22,270 New Ordinary Shares at a price of 89.8 pence per Ordinary Share.

Philipp Prince, Non Executive Director, has subscribed for 4,531 New Ordinary Shares at a price of 89.9 pence per Ordinary Share.

Annemijn Eschauzier, Non Executive Director, has subscribed for 5,440 New Ordinary Shares at a price of 91.9 pence per Ordinary Share.

Details of the Ordinary Shares held by these Directors are detailed in the table below:

Director/ PDMR	Position	Existing interest in Ordinary Shares	Ordinary Shares purchased	Total beneficial interest in Ordinary Shares	Total interest in Company's issued share capital
Rory Shaw	Non-Executive Chairman	56,303	22,270	78,573	0.59%
Philipp Prince	Non-Executive Director	20,232	4,531	24,763	0.19%
Annemijn Eschauzier	Non-Executive Director	-	5,440	5,440	0.04%

The notification set out below, provides further details of such dealings:

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Names	Rory Shaw Philipp Prince Annemijn Eschauzier
2	Reason for the notification
a)	Position/status	Non-Executive Chairman Non-Executive Director Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Feedback plc
b)	LEI	213800UGOF2GT2U2RV90
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 0.50 pence each in Feedback plc
	Identification code	GB00BJN59X09
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			89.8p	22,270
			89.9p	4,531
			91.9p	5,440
d)	Aggregated information
	- Aggregated volume	n/a
	- Price
e)	Date of the transaction	21 December 2022
f)	Place of the transaction	XLON

Enquiries:

Feedback plc Tom Oakley, CEO Anesh Patel, CFO	[phone] [e-mail]
Panmure Gordon (UK) Limited (NOMAD and Broker) Emma Earl/Freddy Crossley (Corporate Finance) Rupert Dearden (Corporate Broking)	[phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Nick Rome/Joe Walker	07748 325 236 or 07407 020 470

About Feedback

Feedback plc helps clinical teams to make better decisions faster for patients. We design products that enhance clinician access to patient data and to their colleagues. Our unique approach centres around individual patient episodes, into which we pull relevant clinical data from hospital systems and around which we build remote clinical teams for collaboration. As a result, we produce a digital infrastructure that makes patient data available to clinicians in multiple settings, in a format that enables them to meaningfully interact with it, providing flexibility to clinicians and free movement of patients between provider settings - clinicians can practice from anywhere and patients can attend any care provider for treatment. 

Our products Bleepa and CareLocker work together to deliver unparalleled value to our customers. Bleepa is our application layer and sits on top of CareLocker as our data layer. Bleepa is a clinician facing platform that displays clinical results from a patient's CareLocker at a certified and regulated quality, that is suitable for clinical use and enables dialogue on a patient-by-patient basis with colleagues through a secure, auditable chat interface that links back to the patient medical record. The CareLocker data storage model is built around the patient. Our vision is one where relevant clinical data is always available to the patient as well as to any care setting that they may attend -  a federated data architecture with the patient as the tenant. 

The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS, the veterinary market and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based revenue model is expected to provide increasing levels of visibility as the Company grows its customer base.

 

END

 

 

DSHPPGWUPUPPGMG